India Pharma Looks To Research, Drug Discovery To Make Rosy 2008 (India)
This article was originally published in PharmAsia News
Executive Summary
Many of India's drug makers see 2008 as a promising year for them and their decision to focus on discovering new drugs and doing research for multinationals. The chairman of Nicholas Piramal India says foreign pharmas finally have realized Indian companies have those capabilities. The realization came near the end of 2007, however, so the Indian industry depended on mergers and acquisitions strategies that largely failed to be fruitful. Indian pharmaceuticals did benefit in 2007 from increased sales in the domestic market. (Click here for more
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.